Our Clinical Trials
 

TCA Cellular Therapy, LLC (TCA-CT) currently has multiple ongoing FDA Human Clinical Trials These clinical trials focus on studies using a single type of stem cell as well as combinations of stem cells. (see below).

In addition, the company is developing clinical protocols (Muscular Dystrophy and Parkinson’s disease) aimed to use autologous (from the same person) or allogeneic (from a different person other than the recipient) stem cells, either immediately after processing ("fresh") or after long-term storage ("cryopreserved").

To review our clinical trials, please click here


Cardiac:

  • Phase I: IND 11643 (1) Repair of infarcted myocardium (heart attack) in patients during bypass surgery and (2) rescue and repair of cardiac muscle after acute myocardial infarction (heart attack). COMPLETE
  • Phase I: IND 13562 Severe Coronary Ischemia (blockages to the heart). COMPLETED.
  • Phase II: IND 13562 Severe Coronary Ischemia (blockages to the heart). PARTIAL CLINICAL HOLD

Vascular:

  • Phase I: IND 13139 Treatment of severe limb ischemia (blockages in the leg). COMPLETE
  • Phase II: IND 13139 Treatment of severe limb ischemia (blockages in the leg). COMPLETE
  • Phase III: IND 13139 Treatment of severe limb ischemia (blockages in the leg). IN PREPARATION

ALS:

  • Phase I: IND 13729 Treatment of Amyotrophic Lateral Sclerosis (ALS). PARTIAL CLINICAL HOLD

Spinal Cord Injuries:

  • Phase I: IND 13981 Treatment of Spinal Cord Injury. OPEN
back to the top